All In Biotech

Free tool

FAERS Monitor: Vabomere

The FDA Adverse Event Reporting System collects reports from patients, clinicians and manufacturers. Counts are unverified reports, not rates: they rise with how widely a drug is used, how long it has been sold and media attention, a report can name several drugs, and a report does not show the drug caused the event.

Last checked: Nov 20, 2026FDA FAERS (openFDA) last updated: Oct 28, 2026Methods & limitations

Reports naming NDA 209776 or its brand name (Vabomere, Meropenem, Vaborbactam). Reports on generic versions are filed under their own applications.

Reports

50

Serious

30

60% of reports

Hospitalization

4

Death reported

11

Any cause; not necessarily from the drug

Most reported reactions

MedDRA preferred terms.

  • off label use19
  • drug ineffective for unapproved indication7
  • death5
  • condition aggravated3
  • drug ineffective3
  • erythema3
  • hypersensitivity3
  • peripheral swelling3
  • rash3
  • acute kidney injury2
  • blood culture positive2
  • creatinine renal clearance increased2
  • drug eruption2
  • drug resistance2
  • headache2

Reports by year received

View as table
YearReports
20189
20199
20208
202110
20222
20236
20242
20253
20261

Disproportionality screen

Proportional reporting ratio (PRR): how much more often each reaction appears in this drug's reports than in the other 21,054,109 FAERS reports. Flagged when PRR is at least 2, chi-squared at least 4 and there are 3 or more reports (Evans criteria). A screening statistic only.

ReactionReportsPRR95% CI lowerChi-squared
creatinine renal clearance increased21128.9289.81,264
blood culture positive2280.972.2313
drug ineffective for unapproved indicationSignal753.727.0312
drug eruption247.512.250
drug resistance232.88.434
off label useSignal199.16.4135
peripheral swellingSignal38.22.713
hypersensitivitySignal36.82.310
erythemaSignal36.12.08
acute kidney injury25.51.44
condition aggravatedSignal34.21.44
rash32.91.02
death52.41.13
headache21.30.30
drug ineffective31.00.30

A high PRR for a reaction that is also the condition being treated (for example "disease progression" for a cancer drug) is expected and is not a safety signal.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.